

# Comparing two different doses of praziquantel in Lao school children to treat infections of *Schistosoma mekongi* and *Opisthorchis viverrini*

<b>Submission date</b> 12/04/2011	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 05/05/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 08/10/2012	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Peter Odermatt

**Contact details**  
Socinstrasse 57  
Basel  
Switzerland  
4002  
+41 61 284 8214  
peter.odermatt@unibas.ch

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N/A

# Study information

## Scientific Title

Efficacy of praziquantel against *Schistosoma mekongi* and *Opisthorchis viverrini*: a randomized, single-blinded dose comparison

## Study objectives

A 75 mg dose (per kilogram of body weight) of praziquantel is more efficacious in clearing a *Schistosoma mekongi* and *Opisthorchis viverrini* infections than a 40 mg dose (per kilogram of body weight) of praziquantel

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

National Ethics Committee, Laos (Ref:103/NECHR, 29/01/2007)

Ethics commission of the State of Basel, Switzerland (Ethikkommission beider Basel, EKBB) (Ref: 255/06, amendment of 14/02/2007)

## Study design

Randomized controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

*Schistosoma mekongi* and *Opisthorchis viverrini* infections

## Interventions

1. Praziquantel 40 mg / kg body weight (1 dose) versus
2. Praziquantel 75 mg / kg body weight (divided into 2 doses of 50 mg/kg + 25 mg/kg, 4 hours apart)

## Intervention Type

Drug

## Phase

Not Applicable

**Drug/device/biological/vaccine name(s)**

Praziquantel

**Primary outcome measure**

Schistosoma mekongi and Opisthorchis viverrini infection clearance (no eggs in 3 stool samples examined with Kato-Katz technique) at 28 and 90 days after treatment.

**Secondary outcome measures**

1. Reduction of intensity of infection (reduction of mean number of S. mekongi and O.viverrini eggs per gram of stool sample assessed by Kato-Katz technique) at 28 and 90 days after treatment
2. Diagnostic sensitivity of increasing number of Kato-Katz thick smears before and 28 days after treatment. 'Gold' standard: 9 Kato-Katz thick smears (applied on a sub-sample of the population)

**Overall study start date**

01/02/2007

**Completion date**

31/05/2007

## **Eligibility**

**Key inclusion criteria**

1. School children (males and females) between 6-16 years

**Participant type(s)**

Patient

**Age group**

Child

**Lower age limit**

6 Years

**Upper age limit**

16 Years

**Sex**

Both

**Target number of participants**

308 (210 at time of registration)

**Key exclusion criteria**

1. Pregnancy
2. Severe illness
3. Non-consent

**Date of first enrolment**

01/02/2007

**Date of final enrolment**

31/05/2007

## **Locations**

**Countries of recruitment**

Lao People's Democratic Republic

Switzerland

**Study participating centre**

Socinstrasse 57

Basel

Switzerland

4002

## **Sponsor information**

**Organisation**

Swiss Tropical and Public Health Institute (Switzerland)

**Sponsor details**

Socinstrasse 57

Basel

Switzerland

4002

+41 61 284 8111

peter.odermatt@unibas.ch

**Sponsor type**

Government

**Website**

<http://www.swisstph.ch>

**ROR**

<https://ror.org/03adhka07>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

Swiss National Science Foundation and Swiss Agency for Development and Cooperation

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/09/2012		Yes	No